Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene

Yoshino,Reiko; Imai,Hisao; Mori,Keita; Takei,Kousuke; Tomizawa,Mai; Kaira,Kyoichi; Yoshii,Akihiro; Tomizawa,Yoshio; Saito,Ryusei; Yamada,Masanobu

doi:10.3892/mco.2014.334

Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene

Authors:
- Reiko Yoshino
- Hisao Imai
- Keita Mori
- Kousuke Takei
- Mai Tomizawa
- Kyoichi Kaira
- Akihiro Yoshii
- Yoshio Tomizawa
- Ryusei Saito
- Masanobu Yamada
View Affiliations

Affiliations: Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, Shibukawa, Gunma 377‑8511, Japan, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan, Clinical Trial Coordination Office, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411‑8777, Japan, Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan
Published online on: July 1, 2014 https://doi.org/10.3892/mco.2014.334
Pages: 731-736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Subsequent therapies confound the ability to discern the effect of first‑line chemotherapy on overall survival (OS). We investigated whether progression‑free survival (PFS), post‑progression survival (PPS) and tumor response were valid surrogate endpoints for OS following first‑line chemotherapy in individual patients with advanced non‑small‑cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor gene mutations. We retrospectively analyzed 35 patients with advanced NSCLC treated with first‑line gefitinib. The associations of PFS, PPS and tumor response with OS were analyzed. PPS was found to be strongly correlated with OS, unlike PFS and tumor shrinkage. The factors significantly associated with PPS were performance status (PS) after first‑line treatment, best response to second‑line treatment and number of regimens used after disease progression. PPS may be a surrogate for OS in this patient population and further therapy after disease progression following first‑line chemotherapy may significantly affect OS. However, a larger study is required to validate these results.

View Figures

View References

1	Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
2	Broglio KR and Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 101:1642–1649. 2009. View Article : Google Scholar : PubMed/NCBI
3	Soria JC, Massard C and Le Chevalier T: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 21:2324–2332. 2010. View Article : Google Scholar : PubMed/NCBI
4	Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
5	Saad ED, Katz A and Buyse M: Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 28:1958–1962. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sundar S, Wu J, Hillaby K, Yap J and Lilford R: A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol. 125:493–499. 2012. View Article : Google Scholar : PubMed/NCBI
7	Petrelli F and Barni S: Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 24:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hotta K, Kiura K, Fujiwara Y, et al: Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One. 6:e266462011. View Article : Google Scholar : PubMed/NCBI
9	Hayashi H, Okamoto I, Morita S, Taguri M and Nakagawa K: Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol. 23:1537–1541. 2012. View Article : Google Scholar : PubMed/NCBI
10	Imai H, Takahashi T, Mori K, et al: Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma. 61:233–240. 2014. View Article : Google Scholar
11	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
12	Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
13	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
14	Inoue A, Kobayashi K, Maemondo M, et al: Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 24:54–59. 2013. View Article : Google Scholar
15	Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
16	Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 8:335–341. 2006. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
18	Johnson KR, Ringland C, Stokes BJ, et al: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 7:741–746. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hotta K, Fujiwara Y, Matsuo K, et al: Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 4:311–317. 2009. View Article : Google Scholar : PubMed/NCBI
20	Weir CJ and Walley RJ: Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med. 25:183–203. 2006. View Article : Google Scholar : PubMed/NCBI
21	Fleischer F, Gaschler-Markefski B and Bluhmki E: A statistical model for the dependence between progression-free survival and overall survival. Stat Med. 28:2669–2686. 2009. View Article : Google Scholar : PubMed/NCBI
22	Foster NR, Qi Y, Shi Q, et al: Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 117:1262–1271. 2011. View Article : Google Scholar
23	Berghmans T, Pasleau F, Paesmans M, et al: ELCWP: Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J. 39:9–28. 2012. View Article : Google Scholar : PubMed/NCBI
24	Tsujino K, Kawaguchi T, Kubo A, et al: Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol. 4:994–1001. 2009. View Article : Google Scholar : PubMed/NCBI
25	Li X, Liu S, Gu H and Wang D: Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol. 138:1963–1969. 2012. View Article : Google Scholar : PubMed/NCBI
26	Tomizawa Y, Fujita Y, Tamura A, et al: Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer. 68:269–272. 2010. View Article : Google Scholar : PubMed/NCBI